Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-09-22
2002-01-22
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C536S024100, C536S023100, C435S455000, C435S377000, C435S375000
Reexamination Certificate
active
06340674
ABSTRACT:
BACKGROUND OF THE INVENTION
The IGF-1 receptor is expressed in many cell types including fibroblasts, epithelial cells, smooth muscle cells, chondrocytes, osteoblasts and several lineages of hemopoietic cells which have IGF-1 receptors and an absolute requirement for IGF-1 for growth in cultures. A review of human cells expressing the IGF-1 receptor and requiring IGF-1 for growth can be found in Baserga and Rubin,
Critical Reviews in Eukaryote Gene Expression,
1993, 3: 47-61; and Goldring and Goldring,
Eukaryote Gene Expression
1991, 1, 301-326. Macaulay,
Br. J. Cancer
1992, 65,311-320, has reviewed the expression of insulin-like growth factors (both IGF-1 and IGF-2) and their receptors in human cancer. Recently, it was shown that IGF-1 peptide analogs may be useful for inhibiting the growth of IGF-1 dependent cells (Pietrzkowski et al.,
Cancer Res.
1993, 53, 1102-1106). Antisense oligonucleotides to mRNA coding for IGF-1 was used to transform rat glioblastoma cells. The cells reversed the transformed phenotype, and acted immunogenic against the parent glioblastoma cell line, completely inhibiting its growth. Trojan et al.
Science,
1993, 259, 94-97 and Trojan et al.,
Proc. Natl. Acad. Sci. U.S.A.,
1992, 89, 4874-4878. However, effective methods of inhibiting growth and causing differentiation of cells are still greatly desired.
SUMMARY OF THE INVENTION
Methods of inhibiting the growth and causing differentiation of undifferentiated cells with antisense oligonucleotides complementary to a region of the IGF-1 receptor are provided. The antisense oligonucleotides of the present invention comprise sequences complementary to regions of IGF-1 receptor RNA. The oligonucleotides comprise a sequence complementary to a region selected from the sequence of IGF-1 receptor. The antisense oligonucleotides include DNA sequences; and antisense RNA oligonucleotides produced from an expression vector. Each of the antisense oligonucleotides of the present invention are complementary to regions of the IGF-1 receptor sequence. The antisense oligodeoxynucleotide of the present invention comprises a sequence complementary to codons −29 to −24 of the signal sequence, for example, SEQ ID NO: 4. The signal sequence of IGF-1 receptor is a 30 amino acid sequence. Contemplated by this definition are fragments of oligos within the 30 amino acid signal sequence. Alternatively, fragments of oligos within SEQ ID NO: 4 are also contemplated. The antisense oligoribodeoxyoligonucleotide, SEQ ID NO: 8 produced from an expression vector comprises a sequence complementary to codons 1 to 309 of the IGF-1 receptor,
FIGS. 7A-7G
. See Ullrich et al.,
EMBO J.,
1986, 5:2503. Contemplated by this definition are fragments of oligos within the coding sequence for the IGF-1 receptor.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5077059 (1991-12-01), Mishima et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5262308 (1993-11-01), Baserga
patent: 5271941 (1993-12-01), Cho-chung
patent: 5272082 (1993-12-01), Santoli et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5460831 (1995-10-01), Kossovsky et al.
patent: WO 91/17253 (1991-11-01), None
patent: WO 93/20691 (1993-10-01), None
patent: WO 92/22486 (1994-10-01), None
patent: WO 94/23034 (1994-10-01), None
patent: WO 96/14746 (1996-05-01), None
patent: WO 97/18241 (1997-05-01), None
patent: WO 97/37010 (1997-10-01), None
patent: WO 99/23259 (1999-05-01), None
Douglas W. Green, et al., Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease, Jul. 2000, American College of Surgeons, pp. 93-105.*
Andrea D. Branch, A Good Antisense Molecule is Hard to Find, Feb. 1998, TIBS vol. 23, pp. 45-50.*
Agrawal et al., “Antisense Oligonucleotide Based Therapeutic Approach: From Laboratory to Clinical Trials,”Antisense Therapy: Efficacy and Delivery of Antisense&Ribozine Oligonucleotide(Feb. 23-25, 1995 London).
Arad et al., “Use of reconstructed Sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA,”Biochem. Biophy. Acta.,1986, vol. 859, pp. 88-94.
Baker et al., “Role of Insulin-like Growth Factors in Embryonic and Postnatal Growth,”Cell,1993, vol. 75, pp. 73-82.
Baserga, The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?,Cancer Research,1995, vol. 55, pp. 249-252.
Baserga and Rubin, “Cell Cycle and Growth Control,”Critical Reviews in Eukaryote Gene Expression,1993, vol. 3, pp. 47-61.
Bayever et al., “Oligonucleotides in the Treatment of Leukemia,”Hematological Oncology,1994, vol. 12, pp. 9-14.
Becker et al., “Proliferation of Human Malignant Melanomas is inhibited by Antisense Oliodeoxynucleotides targeted against basic fibroblast growth factor”,The Embo Jour.,1989, vol. 8, pp. 3685-3691.
Brown, D., “Gene therapy “oversold” by researchers, Journalists,”Washington Post,1995, A1 + A22.
Chomczynski and Sacchi, “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,”Anal. Biochem.,1987, vol. 162, pp. 156-159.
Coghlan, A.,New Scientist,1995, pp. 14-15.
Craig et al., “Sequence Organization of Two Recombinant Plasmids Containing Genes for the Major Heat Shock-induced Protein ofD. melanogaster,” Cell,1979, vol. 16, pp. 575.
Culver, K. et al., TIG, 1994, vol. 10, #5, pp. 174-178.
de Fabritis et al., “In vitro Purging with BCR-BRL Antisense Oligonucleotide does not Prevent Haematologic Reconstitution After Autologous Bone Marrow Transplantation,”Leukemia,1995, vol. 9(4), pp. 661-664.
Dzav, V., et al., TIBTECH, 1993, vol. 11, pp. 205-210.
Feinberg and Vogelstein, “A Technique for Radiolabeling DNA Restriction Endonuclease Fragments to High Specific Activity,”Anal Biochem.,1983, vol. 132, pp. 6-13.
Floros et al., “Induction of Cell DNA Replication in G1-Specific ts Mutants by Microinjection of SV40 DNA,”Exp. Cell Res.,1981, vol. 132, pp. 215.
Gennaro, Alfonso, ed., “Remington's Pharmaceutical Sciences,” 18thEdition, 1990.
Goldring and Goldring, “Cytokines and Cell Growth Control,”Eukaryote Gene Expression,1991, vol. 1, pp. 301-326.
Gritz et al., “Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B phosphotransferase gene and its expression inEscherichia coliandSaccharomyces cerevisiae,” Gene,1983, vol. 25, pp. 179.
Gura, T. et al.,Science,1995, vol. 270, pp. 575-577.
Holt, J. et al.,PNAS,1986, vol. 83, pp. 4794-4778.
Jat et al., “Cell lines established by a temperature-sensitive simian virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature,”Mol. Cell. Biol,1989, 9, p. 1672.
Hiija et al., “Biologic and Therapeutic Significance of MYB Expression in Human Melanona,”Proc. Natl. Acad. Sci.,1994, vol. 91, pp. 4499-4503.
Hug, P. et al.,Biochem. Biophys. Ana.,1991, vol. 1097, pp. 1-17.
Jat et al., “Cell Lines Established by a Temperature-Sensitive Simian Virus 40 Large-T-Antigen Gene Are Growth Restricted at the Nonpermissive Temperature,”Mol. Cell. Biol.,1989, vol. 9, pp. 1672.
Kaleko et al., “Overexpression of the Human Insulinlike Growth Factor I Receptor Promotes ligand-Dependent Neoplastic Transformation,”Mol. Cell. Biol.,1990, vol. 10, pp. 464-473.
Lammers et al., “Differential signalling potential of insulin-and IFG-1-receptor cytoplasmic domains,”EMBO J.,1989, vol. 8, pp. 1369-1375.
Lipson et al., “Transcriptional activity of the human thymidine kinase gene determined by a method using the polymerase chain reaction and an intron-specific probe,”Proc. Natl. Acad. Sci. U.S.A.,1989, vol. 86, pp. 9774-9777.
Liu et al., “Mice Carrying Null Mutations of the Genes Encoding Insulin-like kGrowth Factor 1 (igf-1) and Type 1 IGF Receptor (ifglr),”Cell,1993, vol. 75, pp. 59-72.
Loke, S. et al., “Cancer Topics in Microbiol. And Immunol.,” 1988, vol. 141, pp. 282-289.
Long et al., Loss of the Mestatatic Phenotype in Murine Carcinoma Cel
Baserga Renato
Rubin Raphael
Sell Christian
McGarry Sean
Thomas Jefferson University
Woodcock Washburn Kurtz Mackiewicz & Norris LLP
LandOfFree
Method of inhibiting the proliferation and causing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting the proliferation and causing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting the proliferation and causing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2859801